Renal Cancer, also known as Renal cell adenocarcinoma (RCC) or Kidney cancer, is a group of cancers that start in the kidneys. Symptoms of renal cancer can include lumps in the abdomen, blood in the urine, or chronic back pain. Other symptoms can include rapid weight loss and fever. Kidney cancer is diagnosed when oncologists find abnormal cell growth in the kidney tissue. Over time, these cells form a tissue mass known as a tumor.
Kidney cancer can begin when something in the environment triggers a change in renal cells, causing them to divide uncontrollably. If a malignant or cancerous tumor can spread to other tissues or vital organs, it’s called metastasis. Kidney cancer can metastasize to several organs, including the liver, lungs, or brain.
Based on recent statistics from 2021, Renal cancer is the ninth most commonly occurring cancer in men and the fourteenth-most common cancer type in women. The total number of patients with renal cell adenocarcinoma cancer has nearly tripled since the 1980s. There is an increasing global trend in the incidence of kidney cancer globally, particularly in younger populations and European countries. Doctors have identified several modifiable risk factors for developing kidney cancer. The rapidly increasing incidence of kidney cancer amongst young individuals is quite worrying and requires early intervention with active preventive measures.[1]
Those most susceptible to developing kidney cancer include People between the ages of 65 and 74, who have the highest incidence of developing kidney cancer, and the prevalence of the condition in men is two times that in women. Additionally, Native Americans and people of African descent are disproportionately affected. In contrast to adults, children seldom get kidney cancer. However, every year, between 5000 and 6000 children are diagnosed with Wilms tumors, a rare kind of kidney cancer.
There are many kidney cancer variations, and each type is quite different in the way it develops and mutates over time. Treatment options vary depending on the diagnosis’s type, scale, and severity. The three most common types of renal cancer include:
RCC is the most common form of kidney cancer in the world. RCC is responsible for 85% of all kidney malignancies and is the most frequent kind of kidney cancer in adults. While renal cell carcinoma most often manifests as a solitary tumor in just one kidney, it can also spread to the other organs and is usually seen in patients with chronic liver disease and alcoholic liver cirrhosis. Cancer develops in the tubular epithelium that lines your kidneys (tiny tubes that return nutrients and fluid to your blood). Clear-cell renal cell carcinoma (RCC) accounts for most cases (ccRCC).
Six to seven percent of all kidney malignancies are transitional cell carcinomas. Uterine carcinoma typically develops at the point where the ureter branches off from the kidney proper. Your renal pelvis is the place where your kidneys are located. The ureters and bladder are potentially potential sites of progression for transitional cell cancer. [2]
Renal sarcoma is extremely rare, making up about 1% of all instances of kidney cancer. This disease originates in the kidneys and can spread to other organs and bones if left untreated. Renal sarcoma forms in the connective tissue surrounding the kidneys or the adipose fat around the kidneys. Less than 1 percent of identified kidney cancers are classified as renal sarcoma, and kidney cancer pain location can vary depending on stage.
Wilms tumor is commonly a type of renal cancer in children. Wilms’ tumor is also known as nephroblastoma and most often affects children from the ages 3 to 5 but becomes much less prevalent after the age of 5.
About 9.7% of all malignancies are diagnosed as kidney cancer. On average, around 566,000 people are diagnosed with kidney cancer each year, and renal cancer is more likely to be diagnosed in older people. In its early stages, kidney cancer may not cause any symptoms. Yet, signs and symptoms may emerge as the tumor develops. This is why kidney cancer is frequently not identified until it has already spread to other organs.
Sometimes, the tumors found in the Kidneys are classified as noncancerous (benign). This type of cancer usually doesn’t cause any severe symptoms or discomfort. Benign renal tumors are often found by chance when a patient undergoes imaging tests for other health conditions. Common benign tumors in the kidneys include:
An essential part of dealing with kidney cancer is classifying it into one of four stages. This helps with planning for the appropriate treatment based on stage and severity. The stage of renal cancer will be based on several factors, including staging and diagnostics, to determine which stage is inaccurate.
There are essentially four primary stages:
Lymph nodes are like little “filters,” collecting and storing white blood cells that may be used to fend against infections. To measure the level of dysfunction in a patient’s lymph nodes and the size of tumors, a doctor utilizes radiology scans such as CT and MRI, along with biological samples (via biopsy) from tumors, to establish the extent of the disease.
Grades are assigned to tumors to reflect how their cells deviate from normality. Grading can also estimate the rate of tumor growth. High-grade tumors are characterized by rapidly dividing abnormal cells that don’t resemble healthy tissue. It is common for high-grade tumors to develop and spread faster than low-grade ones.
To reach a diagnosis, an oncologist looks through a patient’s medical history records and does a preliminary physical examination, looking for signs of kidney cancer. They may also request tests that aid in detecting and evaluating cancer. Indicators that may be used in such examinations are:
Major risk factors associated with cancer in the kidneys include:
Having any of these risk factors does not mean you will automatically get kidney cancer. It’s also possible that patients can have none of these symptoms but still get the disease.[4]
When a patient is diagnosed with kidney cancer, oncologists first try to determine if the cancer tumors have spread and, if so, how far. They can then use the patient’s cancer stage and current health to discuss the best treatment options with the highest survival chances.
Surgery is still considered the first option for treatment for benign kidney tumors or non-metastasized kidney cancer. Laparoscopic surgeries offer minimally invasive surgery and only need small incisions in the patient’s abdomen. Doctors can then insert a small camera and other medical instruments to target and destroy the tumor. Recent clinical trials have shown that laparoscopic surgery is equally effective as previous surgery but allows for a much easier recovery.
Doctors often employ a strategy called “watchful waiting” or “active surveillance” for certain patients with tumors, mainly when the cancer is slow-growing, minor, or asymptomatic. This approach involves closely monitoring the tumor for abnormal growth or changes over time without immediately resorting to treatment such as surgery, radiation, or chemotherapy. Regular
Transitioning from active surveillance to more aggressive treatment depends on several critical factors. The patient’s age is considered because younger individuals may tolerate more intensive treatments better and have a longer life expectancy, making long-term outcomes a crucial consideration. The patient’s overall health also plays a vital role, as those with other severe health conditions may face higher risks from invasive treatments and may benefit from delaying or avoiding them.
The size and location of the tumor are key determinants, as tumors in sensitive or vital areas of the body might require earlier intervention due to the risk of complications. Tumors that are growing near critical structures like blood vessels or nerves or in places where they could obstruct organ function may necessitate prompt treatment even if the cancer appears slow-growing. Lastly, the rate of growth observed over time is a significant factor. A tumor that remains stable over months or years might continue under surveillance, but if imaging reveals an increase in size or changes in the tumor’s characteristics, a more proactive treatment plan may be required to prevent further complications.
Ultimately, active surveillance aims to balance the benefits and risks, avoiding unnecessary treatments when the tumor remains stable while acting decisively if there are signs of progression. This individualized approach helps patients maintain their quality of life while addressing the potential dangers posed by the tumor.
Biologic-based therapies such as NK Cell Therapy, also known as Immunotherapy, are a new type of kidney cancer treatment designed to increase our body’s defense mechanisms to fight cancer. mRNA technology and Biological therapies can use autologous materials (made by the patient’s body) or allogenic materials (cultured inside a laboratory) to target, restore, and boost the immune system function. It can be used to:
Most patients diagnosed with Renal cell carcinoma (RCC) are treated with combinations of radiation therapy, chemotherapy, or surgery. Radiation-based therapies are disadvantageous as the high-energy particle rays do not target the cancer cells and destroy healthy cells, causing severe side effects. The levels of radiation exposure in chemotherapeutic doses must be limited to avoid organ toxicity. Therefore, RCC staging (TNM system) qualified therapies require more precisely targeted treatments capable of killing cancer cells while ignoring the healthy cells.
Combining modern immunological cancer therapies and UC-MSC+ stem cells uses a more holistic approach. It is significantly less toxic while maintaining similar and often better results depending on the type, age, and diagnosis stage. Treatment of RCC and immune-boosting therapies are also more effective in achieving long-term tumor immunosurveillance while reducing the chance of relapse.
Immunological therapies for kidney cancer can increase long-term disease-free survival and are prescribed as adjuvant therapy for patients with low white blood cell counts. Stem cell therapy for renal cancer (renal carcinoma) helps boost a patient’s immune system with a naturally produced growth factor to enhance the cancer-fighting capacity.[5]
Immunotherapy for kidney cancer has become a viable standard-of-care treatment and, in some cases, a complete cure. Immunotherapies manipulate or mobilize the patient’s immune system to treat or cure kidney cancer. Immunological therapies can also be performed via manipulation of genes using Dendritic cells (DCs), Immune modulators, monoclonal antibodies therapy, adoptive cell transfer, and the new oncolytic virus therapy, which is a virus-based delivery system of modified genes where the payload uses the viruses as a host to carry past the patient’s immune system.
Patients who are diagnosed with stage 3 kidney cancer who initially might have responded well to medications that target PD-1 protein (checkpoint inhibitors) can, over a short time, develop resistance to these therapies, significantly if cancer has metastasized from its primary location to spawn additional kidney lesion and tumors. In such cases, CAR T Cells & genes encoded with tumor-associated antigens (TAA) induce an adequate response from the immune system.
Earlier clinical trials on late-stage kidney cancer focused on identifying the proliferating progenitor cells (CD34+) in human blood. These progenitor cells are stimulated by cytokines (GM-CSF and TNF-alpha) to differentiate into dendritic cells rapidly. In some cases, combining IL-4 and GM-CSF helps generate significantly larger quantities of cancer-fighting dendritic cells from monocytes and macrophages.
Immunological therapy for kidney cancer might soon be the gold standard in the treatment of renal tumors for these reasons:
The Regeneration Center offers an alternative treatment for kidney cancer that can treat or reverse symptoms depending on the patient’s stage. The best defense from any cancer is first being informed about the disease to make an informed decision about biological treatment for cancer using stem cells.
Our stem cell therapy for kidney cancer is explicitly customized to patient needs. The individualized protocol helps patients fight cancer using traditional cancer treatment and alternative natural cellular-based therapies. For nearly two decades, our approach to integrated healthcare has relied on research-based treatment plans that are comprehensive and specific to patient medical needs to ensure the highest chances of success. The Regeneration Center offers a holistic approach to modern healthcare. We strive to fight cancer and alleviate underlying symptoms that can increase the patient’s quality of life. Cancer stem cell treatment plans also help patients achieve long-term remission rates by addressing the root cause of the disease and not just its symptoms.
Some herbal-based treatments might help treat some symptoms associated with kidney cancer. However, patients diagnosed with cancer need to be extra cautious before digesting an herbal remedy from unknown sources. A compromised renal system may have a much harder time metabolizing substances. Since many herbal preparations and extracts are alcohol-based, kidney cancer patients should always double-check all the ingredients before taking any herbs. Furthermore, some herbal supplements for kidney cancer can cause excessive bleeding and prevent blood from clotting properly.
Primary kidney cancer can be defeated. Our goal is to heal the body from the inside out and help patients achieve the most prolonged possible remission rates. Our natural cell-based approach to healthcare means we will work with you and your primary care doctor to determine the best overall treatment options. Our treatment evaluation for kidney cancer does require a review of current medical records. For patients who, for some reason, are not responding to traditional treatments or those for whom surgery is not a good option, our team can review your Radiology scans (CT, ultrasound, or MRI) and lab tests to target the tumor(s) better and destroy them using minimally invasive techniques. We provide access to innovative kidney cancer treatment techniques and immunotherapies when appropriate. The Regeneration Center also offers its patients comprehensive follow-up care and survivorship programs ( In Thailand only) for patients recovering from kidney cancer.
The outlook for patients diagnosed with renal cancer has never been better. Thanks to modern medicine, many people survive the disease. The Regeneration Cancer Center has cared for patients worldwide who were diagnosed with different types of kidney lesions and stages of kidney cancer. Please contact us today to learn more about our treatment protocols and biological therapy for kidney cancer.
[1] ^ Linehan WM, Schmidt LS, Crooks DR, Wei D, Srinivasan R, Lang M, Ricketts CJ. The Metabolic Basis of Kidney Cancer. Cancer Discov. 2019 Aug;9(8):1006-1021. doi: 10.1158/2159-8290.CD-18-1354. Epub 2019 May 14. PMID: 31088840.
[2] ^ Turajlic S, Swanton C, Boshoff C. Kidney cancer: The next decade. J Exp Med. 2018 Oct 1;215(10):2477-2479. doi: 10.1084/jem.20181617. Epub 2018 Sep 14. PMID: 30217855; PMCID: PMC6170181
[3] ^Dziedzic K, Pleniceanu O, Dekel B. Kidney stem cells in development, regeneration and cancer. Semin Cell Dev Biol. 2014 Dec;36:57-65. doi: 10.1016/j.semcdb.2014.08.003. Epub 2014 Aug 13. PMID: 25128731.
[4] ^Bi LK, Zhou N, Liu C, Lu FD, Lin TX, Xuan XJ, Jiang C, Han JL, Huang H, Zhang CX, Dong W, Liu H, Huang J, Xu KW. Kidney cancer cells secrete IL-8 to activate Akt and promote the migration of mesenchymal stem cells. Urol Oncol. 2014 Jul;32(5):607-12. doi: 10.1016/j.urolonc.2013.10.018. Epub 2014 Jan 10. PMID: 24412633.
[5] ^ Fang P, Zhou L, Lim LY, Fu H, Yuan ZX, Lin J. Targeting Strategies for Renal Cancer Stem Cell Therapy. Curr Pharm Des. 2020;26(17):1964-1978. doi: 10.2174/1381612826666200318153106. PMID: 32188377